Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.63 |
| ▸ | CD63 | P08962 | 5/20 | 0.63 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299467 | 1.00 | SYK (0.63) | SYKCD63JAK2TBK1TLR9 | |
| SCHEMBL30299723 | 0.93 | SYK (0.55) | SYKCD63JAK2TBK1TLR8 | |
| SCHEMBL30299501 | 0.85 | SYK (0.73) | SYKCD63JAK2 | |
| SCHEMBL25292590 | 0.85 | SYK (0.73) | SYKCD63JAK2 | |
| SCHEMBL25797067 | 0.84 | TBK1 (0.46) | SYKCD63JAK2TBK1TLR9 | |
| SCHEMBL25244153 | 0.82 | SYK (0.57) | SYKCD63JAK2TBK1TLR9 | |
| SCHEMBL25293760 | 0.81 | SYK (0.62) | SYKCD63JAK2TBK1BTK | |
| SCHEMBL30299609 | 0.81 | SYK (0.62) | SYKCD63JAK2TBK1BTK | |
| SCHEMBL17536353 | 0.78 | SYK (0.80) | SYKCD63JAK2 | |
| SCHEMBL25797068 | 0.77 | SYK (0.59) | SYKCD63JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577248-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2026-03-17 | — | — | US | claimed |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-06-29 | — | — | US | claimed |
| US-12577248-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885CD63 2242/4885JAK2 17/4885 |
| US-12577248-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors | SYK, BTK, TYRO3 | SYK 1/4885CD63 4834/4885JAK2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.